A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis.
The acute-phase protein serum amyloid A (SAA) is a clinically useful marker of inflammation and associates strongly with increased risk of cardiovascular events. Chronically elevated SAA concentrations may contribute to physiological processes that lead to atherosclerosis, including endothelial dysfunction, an early and predictive event in the development of cardiovascular disease. Accumulating data suggest that SAA can be a direct mediator in the development and progression of atherogenesis and atherothrombosis. SAA may affect key events underlying acute coronary syndromes, including cholesterol transport, contribute to endothelial dysfunction, promote thrombosis, and enhance leukocyte trafficking and activation. This review summarizes the evidence supporting a role for SAA as a potential regulator of inflammation and endothelial dysfunction, which underlie the adverse outcomes that complicate coronary artery disease. The findings suggest that novel therapeutic strategies to reduce SAA levels and/or oppose the actions of SAA may have beneficial effects in patients with coronary artery disease.
Concord Repatriation General Hospital, Sydney Medical School, University of Sydney, Concord, New South Wales, Australia.
Susan
S
Hua
Changjie
C
Song
Carolyn L
CL
Geczy
S Ben
SB
Freedman
Paul K
PK
Witting
D000818:Animals; D050197:Atherosclerosis / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D008075:Lipoproteins, HDL / Q000378:metabolism / Q000502:physiology*; D018384:Oxidative Stress / Q000502:physiology*; D000685:Serum Amyloid A Protein / Q000378:metabolism / Q000502:physiology*
D008075:Lipoproteins, HDL; D000685:Serum Amyloid A Protein